Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition-Reference-Cited by-同舟云学术

Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition

Published:2020-03-17 Issue:4 Volume:36 Page:763-775
ISSN:0931-041X
Container-title:Pediatric Nephrology
language:en
Short-container-title:Pediatr Nephrol

Author:

Benigni Ariela,Buelli Simona,Kohan Donald E

Publisher

Springer Science and Business Media LLC

Subject

Nephrology,Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s00467-020-04518-2.pdf

Reference116 articles.

1. Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415

2. Kohan DE, Barton M (2014) Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86:896–904

3. Neuhofer W, Pittrow D (2009) Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Investig 39(Suppl 2):50–67

4. Barton M, Yanagisawa M (2008) Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86:485–498

5. Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12:2832–2837

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lupus nephritis;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Weibel-Palade bodies: function and role in thrombotic thrombocytopenic purpura and in diarrhea phase of STEC-hemolytic uremic syndrome;Pediatric Nephrology;2024-07-05

3. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety;Kidney Medicine;2024-06

4. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy;Nephrology Dialysis Transplantation;2024-01-25

5. Pathophysiology of Hypertension;Hypertension;2024